• Latest
    • Big pharma
    • Biotechnology
    • CRISPR
    • Generics
    • Unified Patent Court
  • Regions
    • Americas
    • Europe
    • Asia
    • Asia-Pacific
  • Careers
  • Events
    • Conferences
    • Conference Videos
    • Webinars
  • Directory
  • Magazines
  • About
  • Contact
  • Newsletter
  • Login
  • Subscribe
  • Home
  • About
  • Contact
  • Newsletter
  • Login


Subscribe
  • Home
  • Trends at the Patent Trial and Appeal Board of the US Patent and Trademark Office: Is the Pendulum Beginning to Swing for Owners of Life Sciences Pate
18 March 2021

Trends at the Patent Trial and Appeal Board of the US Patent and Trademark Office: Is the Pendulum Beginning to Swing for Owners of Life Sciences Pate

The Patent Trial and Appeal Board is an important forum for determining a US patent’s validity. Since 2012, when inter partes review of US patents began, the PTAB’s cancellation rate for challenged patents has varied dramatically.

Already registered?

Login to your account


If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.

For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk




Editor's picks

Regeneron and CureVac: UPC ‘cannot be ignored’
Unified Patent Court
Regeneron and CureVac: UPC ‘cannot be ignored’
4 November 2025

Editor's picks

Unified Patent Court
Regeneron and CureVac: UPC ‘cannot be ignored’
4 November 2025
Americas
Why AI is changing the patent rules faster than anyone can keep up
24 October 2025
Americas
LSPN panel unpacks critical IP risks in deal-making
23 October 2025
Americas
A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order
23 October 2025
Americas
Data and delivery: Inside AI's inventorship dilemma
21 October 2025
Americas
Top pharma, biotech, and medtech experts gather at LSPN Fall
21 October 2025

More features

Regeneron and CureVac: UPC ‘cannot be ignored’
US generics company wins patent battle over Merck Serono’s blockbuster MS drug
Novartis counsel warns: ‘Don’t let AI develop without our input’
Squires: ‘Inherited patent backlog was an absolute dumpster fire’
Is Hatch-Waxman litigation for orphan drugs working?
Delegates descend upon Washington, DC for AIPLA Annual Meeting
Novo Nordisk counters rival with $9bn bid for obesity drug developer
‘We're being attacked from all sides’: Thermo Fisher Scientific counsel

  • Home
  • News
  • About us
  • Contact
  • Terms of Use
  • Privacy Policy
  • Terms of Subscription

LSIPR
Newton Media Ltd
Kingfisher House
21-23 Elmfield Road
BR1 1LT
United Kingdom

  • Twitter
  • Linkedin